Just days after LabCorp agrees to acquire BioReference from OPKO, LabCorp agrees to buy Myriad Prenatal Health assets for $210M.
Here, we let Chat GPT write the full case, including the assets, their origins, and how Myriad's public discussion of the business evolved over four quarters.
As always with these reports, they are AI generated reported and not ground truth. However they service as examples of current AI capabilities to understand requests, research, organize, and write.
Summary. Myriad’s $210 million prenatal divestiture marks a strategic retreat from a business assembled through acquisitions and expanded through internal innovation. Labcorp gains four products, an established customer base, and FirstGene, launched only three months earlier. Across four earnings calls, management’s narrative shifted from recovery after ordering disruptions to persistent commercial weakness and portfolio review. The evidence does not establish that software problems caused the sale. A stronger interpretation combines disappointing recovery, competitive pressure, reimbursement friction, and oncology investment priorities. For Labcorp, the transaction offers consolidation and integration opportunities; for Myriad, it exchanges uncertain future growth for cash and strategic focus.
About the Labcorp Transaction
The transaction. Myriad has agreed to sell its Prenatal Health testing business to Labcorp for $210 million in cash, plus inventory at closing. Labcorp projects approximately $160 million of first-year revenue, slight first-year adjusted earnings accretion, and profitability reaching its average Diagnostics segment margins by the end of year two. Closing is expected by early 2027, subject to regulatory clearance and other conditions. These are announced expectations, not completed results. The joint announcement is available here. Labcorp
The SEC filing adds useful substance. This is an asset transaction involving specified assets and liabilities, employee offers, a patent license agreement, and transition services. It is therefore more than a transfer of four trademarks, but it is not an acquisition of Myriad itself. The contractual initial outside date is February 19, 2027, with a potential regulatory extension to October 19, 2027. Certain regulatory termination circumstances could require Labcorp to pay a $10.5 million fee. sec.gov
What “Prenatal Health” means at Myriad. The company’s dedicated prenatal screening webpage describes a portfolio spanning reproductive carrier assessment, fetal chromosome screening, fetal single-gene risk assessment, and early fetal-sex prediction. The four products have distinct purposes:
| Product | Principal purpose | Place in the portfolio |
|---|---|---|
| Foresight | Identifies carriers of inherited conditions that could be transmitted to offspring | Relevant before pregnancy as well as during pregnancy |
| Prequel | Uses maternal blood to screen for fetal chromosomal conditions | Myriad’s established noninvasive prenatal screening product |
| SneakPeek | Predicts fetal sex from early pregnancy | A consumer-facing offering, including at-home access |
| FirstGene | Combines patient carrier status, fetal single-gene risk, fetal chromosome screening, and fetal RhD assessment | An integrated prenatal assay with one maternal blood draw |
Myriad markets FirstGene for use beginning at eight weeks, without requiring a reproductive-partner sample. Its four components should not be confused with four separate acquisitions. Nor should its carrier component be assumed to reproduce the full breadth of every Foresight panel. Myriad Genetics
An important boundary: Myriad is selling prenatal testing, not all testing sold through women’s-health practices. Historically, its Women’s Health business included both prenatal products and hereditary cancer testing for unaffected patients. MyRisk remains in the Cancer Care Continuum category. Thus, the transaction does not imply abandoning OB/GYN relationships or hereditary breast and ovarian cancer assessment. investor.myriad.com
Where the assets came from—and what Myriad paid. The portfolio combines two acquisitions with subsequent development.
| Origin | Date | Financial terms | Principal contribution |
|---|---|---|---|
| Counsyl acquisition | Announced May 28, 2018; completed July 31, 2018 | $375 million announced; subsequent SEC reporting recorded $405.9 million of total consideration | Foresight and the prenatal screening business then branded Prelude, subsequently Prequel |
| Gateway Genomics acquisition | November 1, 2022 | $67.5 million upfront, with up to $32.5 million contingent consideration | SneakPeek and its consumer distribution capabilities |
| Myriad product development | Subsequent years; FirstGene commercially launched July 21, 2026 | No separate FirstGene acquisition price identified | Integration and extension of prenatal technologies into FirstGene |
The Counsyl announcement and closing release establish the 2018 chronology. The Prelude-to-Prequel lineage is also documented in the scientific literature. investor.myriad.com
The $375 million versus $405.9 million distinction deserves attention. The SEC acquisition note reports $278.5 million in cash and approximately three million Myriad shares valued at $127.4 million. Those shares were valued at the closing-date market price. The widely cited announcement price therefore differs from the subsequently recorded consideration. sec.gov
Gateway should not casually be described as a $100 million acquisition: that was the maximum upfront-plus-contingent opportunity. Myriad’s 2024 annual report valued the remaining Gateway contingent consideration at zero because achievement of the targets was not considered probable. myriad.gcs-web.com
Using Counsyl’s announced price plus Gateway’s upfront payment produces $442.5 million. Substituting Counsyl’s subsequently reported consideration produces $473.4 million. Both substantially exceed today’s $210 million headline sale price.
That comparison is striking, but it is not an investment-return calculation or an accounting loss estimate. The purchases and sale have different asset and liability boundaries; Myriad operated the businesses for years; cash flows occurred in the meantime; and additional development spending created products that did not exist at acquisition.
The original strategy was broader than prenatal testing. In 2018, Myriad envisioned combining Counsyl’s reproductive products with hereditary cancer testing to increase physician reach and provide a comprehensive women’s-health offering. In 2022, Gateway added an earlier consumer entry point: families buying SneakPeek could become aware of Myriad’s other genetic tests. investor.myriad.com
One interpretation is that the 2026 sale reverses that organizing principle. The earlier strategy emphasized a shared customer and life-stage relationship. The emerging strategy emphasizes disease-specific investment, particularly cancer. A common ordering physician does not necessarily make two businesses equally attractive destinations for capital.
The Four Call Record
The four-call record. The relevant window is Q3 2025, Q4 2025, Q1 2026, and Q2 2026. Myriad’s next quarterly call is November 4, after this announcement.
The reported prenatal figures provide an anchor for interpreting management’s language:
| Reported quarter | Prenatal revenue | Revenue change, year over year | Volume change, year over year |
|---|---|---|---|
| Q3 2025 | $44.5 million | +2% | −3% |
| Q4 2025 | $44.9 million | Flat | −6% |
| Q1 2026 | $41.9 million | −15% | −12% |
| Q2 2026 | $39.8 million | −16% | −9% |
These are the prenatal product-category figures, not total Women’s Health revenue. The Q2 call rounded revenue to $40 million; the financial table reports $39.8 million. investor.myriad.com
November 3, 2025: recovery remained the working assumption. On the Q3 call, management described improvement after the second-quarter ordering disruption. Legacy Prequel and Foresight volumes were approximately flat year over year. The broader category’s 3% volume decline reflected lower SneakPeek demand, an important distinction between the clinical-testing narrative and the aggregate figures. Roic AI
Analysts Puneet Souda and David Westenberg pressed on competitive share shifts and why the ordering-system effects persisted. Management’s explanation was that large customers already used multiple laboratories and had shifted volume away during the disruption. Fixing the operational problem did not automatically restore their orders.
FirstGene remained a prospective growth catalyst. Nevertheless, oncology was already the first strategic priority, while prenatal and mental health were expected to grow within disciplined resource allocations. The emerging hierarchy preceded the sale: prenatal remained strategically useful, but oncology had first claim on incremental investment. Roic AI
February 23, 2026: the recovery timetable became more qualified. On the Q4 call, management described renewed prenatal volume softness and warned of a difficult first-quarter comparison. It still anticipated recovery from Q2 onward, supported by a more focused sales effort and FirstGene.
Analysts asked whether competition was contributing and how widespread the remaining customer problem was. Brian Donnelly said accounts unaffected by the ordering issue were growing at or above market. Sam Raha described the original implementation as a “self-induced error” and said the company had reviewed its other ordering systems.
FirstGene remained scientifically encouraging, but the CFO said guidance did not assume a sizable direct contribution from it. The product could also reopen conversations about the existing portfolio.
The important change was a more conditional recovery thesis: customer reactivation, commercial execution, and a new-product conversation all needed to work. The Motley Fool
May 5, 2026: analysts challenged the recovery premise directly. On the Q1 call, Brandon Couillard questioned whether annual prenatal volume growth remained realistic, given weak year-over-year results and only modest sequential improvement.
Management pointed to a dedicated prenatal sales team and FirstGene. Crucially, Raha said the order-to-report operational problems had been absent for several quarters. The remaining challenge was commercial execution.
The call also clarified FirstGene’s economic thesis: Myriad intended to launch using existing billing codes, expected higher average revenue per test, and believed that would more than offset somewhat higher processing costs. A dedicated code was a possible later development.
This was still an investment-and-recovery story. But it was explicitly no longer a story about waiting for broken software to be repaired. The unresolved question was whether restored operations and differentiated science would translate into renewed ordering and attractive economics. investing.com
July 30, 2026: disappointing execution became a portfolio question. On the Q2 call, management acknowledged less progress than expected in prenatal, citing sales-force expansion timing and competitive dynamics. It reported declines in both volume and average revenue per test. FirstGene had launched the previous week, and some customers were returning to trial it.
At the corporate level, management described a rigorous portfolio evaluation. The accompanying release connected the strategic review to growth, profitability, and liquidity. Myriad reduced its annual revenue outlook and suspended adjusted EBITDA guidance while assessing its operational initiative, Ascend.
The question had changed from how quickly prenatal would recover to where Myriad should allocate capital. That is the clearest public bridge to the October transaction. It does not establish when negotiations began or that management had already decided to sell during the July call. investing.com
Could a software problem really explain the divestiture? Your skepticism is warranted. The evidence supports a narrower causal chain:
- Management attributed an initial loss of customer volume to the ordering rollout.
- Management repeatedly distinguished fixing operations from recovering customer orders.
- Subsequent disclosures broadened the problem to commercial execution, competition, and reimbursement.
- The eventual sale was presented as the outcome of a strategic review.
The plausible mechanism is persistent customer displacement after a temporary disruption. A practice that already sends specimens to several laboratories can redirect orders quickly. Once another laboratory becomes the established workflow, the original provider must win those orders back.
But plausibility is not proof of magnitude. Public disclosures do not quantify how much lost revenue was attributable to the implementation, identify the affected accounts, or isolate the effects of competitor offerings and payer behavior. They certainly do not demonstrate that the software episode was the decisive reason for selling.
The stronger interpretation is that prenatal’s recovery disappointed while other businesses competed for management attention and investment. The incident may have contributed to that situation; the transaction reflects a broader judgment about ownership and capital allocation.
What the price and revenue tell us. The $210 million headline price represents approximately 1.31 times Labcorp’s projected first-year revenue. Myriad’s latest four reported prenatal quarters total approximately $171.1 million; annualizing Q2’s $39.8 million produces $159.2 million. Labcorp’s $160 million forecast is therefore close to the latest quarterly revenue pace. These are calculations from the disclosed figures, not company-provided valuation multiples. Labcorp
That alignment suggests a transaction underwritten around the current business, with potential improvement to follow. It does not demonstrate that Labcorp assigned FirstGene little value: the companies have not disclosed a product-level valuation or revenue bridge.
Nor does Myriad’s claim of growth accretion mean selling the business increases total revenue dollars. Removing a slower-growing or declining business can improve the remaining company’s percentage growth rate while reducing its size. Profitability improvement depends on the earnings contribution sold, expenses eliminated, and overhead left behind.
Myriad ended Q2 with $115.2 million in cash and reported $30.8 million of first-half adjusted free-cash outflow. Against that background, $210 million of gross proceeds is financially consequential, although it cannot simply be added to June cash to forecast the closing balance. sec.gov
Why Labcorp can see opportunity in a business Myriad is exiting. Labcorp already offers MaterniT prenatal screening and Inheritest carrier screening. Its MaterniT lineage includes the 2016 Sequenom acquisition. It also markets a combined prenatal collection kit designed to simplify ordering and specimen handling. This acquisition expands an established reproductive genetics business. International Distributors
The potential benefits are therefore partly operational: serving additional accounts through existing infrastructure, spreading costs across greater volume, coordinating collection and ordering, and choosing how to position overlapping and differentiated assays.
Those are analytical possibilities, not disclosed integration commitments. The announcement does not specify which brands, laboratories, platforms, or commercial arrangements Labcorp will ultimately retain. Its two-year margin target indicates that integration matters; the buyer is not promising immediate achievement of mature segment profitability.
For Myriad, selling can be rational even if FirstGene is promising. The relevant comparison is between the risk-adjusted value of continuing to fund prenatal and the value of cash, reduced complexity, and investment capacity elsewhere. For Labcorp, an existing operating platform may change that calculation.
The BioReference connection. The two announcements occurred five days apart. On October 15, Labcorp agreed to acquire selected BioReference assets for $722 million upfront, subject to adjustment, plus a possible $150 million 4Kscore earnout. Labcorp projected approximately $250 million in first-year revenue from that transaction. Both transactions remain subject to closing conditions. Labcorp
| Announced acquisition | Headline upfront price | Projected first-year revenue | Simple price/revenue ratio |
|---|---|---|---|
| Selected BioReference assets | $722 million | Approximately $250 million | 2.89× |
| Myriad Prenatal Health | $210 million, plus inventory | Approximately $160 million | 1.31× |
These ratios are descriptive, not directly comparable valuation judgments. They omit differences in margins, growth, liabilities, intellectual property, earnouts, and integration requirements.
The shared strategic pattern is more instructive: sellers are narrowing their focus while Labcorp is expanding the range and scale of diagnostic services it can operate. The same laboratory business can represent organizational complexity to one owner and an attractive addition to another.
Details to watch in the November discussion. The purchase agreement specifies that Myriad retains pre-closing accounts receivable. Selling the operating business therefore does not transfer every legacy collection issue to Labcorp. It also distinguishes purchased assets from shared systems and other retained assets, reinforcing that separation itself requires work. sec.gov
The most useful additional disclosures would be the business’s earnings contribution, stranded overhead, expected separation costs, net proceeds, and commitments to FirstGene development. Without those, it is premature to describe either an obvious bargain for Labcorp or a fully quantified financial improvement for Myriad.
The five most surprising features
Counsyl’s familiar $375 million price understates the subsequently reported consideration. The SEC recorded $405.9 million. Adding Gateway’s $67.5 million upfront payment makes the historical acquisition spending substantially larger than the current sale price—even before subsequent development investment. That is a revealing capital-allocation comparison, although not a measure of realized loss. sec.gov
FirstGene was commercially launched only 91 days before the sale announcement. Labcorp is acquiring a newly introduced platform alongside established products. The public record offers too little commercial history to treat the sale as a verdict on FirstGene’s market success or failure. globenewswire.com
The old women’s-health bundling strategy is being unwound selectively. Myriad retains hereditary cancer testing, including testing delivered through women’s-health practices. What is being separated is the reproductive portfolio that earlier acquisitions were intended to combine with it. investor.myriad.com
Labcorp’s first-year forecast almost exactly matches the latest quarterly revenue pace. Annualized Q2 prenatal revenue is $159.2 million versus Labcorp’s approximately $160 million forecast. The announced economics appear grounded in the existing business rather than requiring an immediate dramatic rebound. sec.gov
Labcorp is buying into a field where it is already a substantial participant. Existing MaterniT and Inheritest capabilities make this a consolidation and integration opportunity, with FirstGene adding a distinct product proposition. The central strategic wager is that the portfolio will be worth more within Labcorp’s operating system than as an investment priority within Myriad. That final proposition is the deal’s economic hypothesis—not yet its demonstrated outcome. International Distributors
##
